Nantkwest Inc (NASDAQ:NK) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: September 19, 2016
Only yesterday Nantkwest Inc (NASDAQ:NK) traded 9.21% lower at $8.38. NK’s 50-day average is $7.91 and its two hundred day moving average is $7.70. With the last stock price close up 8.80% relative to the two hundred day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the date range. 515,924 shares of NK were exchanged, up from ann avg. volume of 276,980.
Zacks Investment Research has downgraded Nantkwest Inc(NASDAQ:NK) to Sell in a report released 9/20/2016.
A total of 6 brokerages have issued a report on the stock. Zero rate the stock a strong buy, 0 rate the company a buy, 0 analysts rate the company a hold, 0 rate the stock to underperform, and lastly 0 firmsrate the company as sell with a 12-month target of $26.17
Nantkwest Inc has a one-year low of $5.43 and a 52 week high of $19.43. NK’s total market value is presently $0.0.
General Information About Nantkwest Inc (NASDAQ:NK)
NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs). It develops aNK product candidates for the treatment of virally-induced cancers, such as polyoma virus induced Merkel Cell Carcinoma, Human Papilloma Virus induced cervical, and head and neck cancers, as well as infectious diseases, such as Ebola and other serious viral, fungal and bacterial infections. It also develops haNKs for the treatment of solid tumors, breast cancer, multiple myeloma, lymphoma and colorectal cancer, and taNKs for the treatment of brain cancer, breast cancer, and non-hodgkin lymphoma and myelodysplastic syndrome.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.